Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.08.2023 | Case report

Fingolimod/rituximab

COVID-19 and reduced humoral immunity: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Konig M, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry 94 : 19-22, No. 1, Jan 2023. Available from: URL: https://jnnp.bmj.com/content/94/1/19.long Konig M, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry 94 : 19-22, No. 1, Jan 2023. Available from: URL: https://​jnnp.​bmj.​com/​content/​94/​1/​19.​long
Metadaten
Titel
Fingolimod/rituximab
COVID-19 and reduced humoral immunity: 3 case reports
Publikationsdatum
01.08.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-44307-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Epidemiology clinical study

Prescription drug-induced delusion

Case report

Multiple drugs

Case report

Heparin

Case report

Carbamazepine

Case report

Isotretinoin

Case report

Multiple drugs